{
  "ticker": "CU6",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959122",
  "id": "02959122",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250617",
  "time": "0936",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250617/pdf/06kth1v75ydb12.pdf",
  "summary": "**Key Material Information Summary:**  \n\n- **Commercial Manufacturing Agreement signed with SpectronRx** for large-scale production of **64Cu-SAR-bisPSMA** (diagnostic radiopharmaceutical).  \n- **Capacity**: Up to **400,000 patient-ready doses annually** from SpectronRx\u2019s Indiana facility, scalable via optional regional US hubs.  \n- **Strategic Impact**: Ensures **nationwide US distribution** (all 50 states) upon FDA approval; reinforces supply chain resilience for commercial rollout.  \n- **Timeline**: Agreement effective **17 June 2025** (5-year term), aligning with Phase III trials (**CLARIFY**, **AMPLIFY**) and future NDA submission.  \n\n*Rationale: Directly addresses commercial readiness and scalability, critical for valuation given pending Phase III results and market potential.*",
  "usage": {
    "prompt_tokens": 2772,
    "completion_tokens": 171,
    "total_tokens": 2943,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-16T23:48:17.857747"
}